Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Memantine, sold under the brand name Namenda among others, is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is taken by mouth.
The analysis highlights History, Community, Culture and Applications as prominent areas in the source structure around Memantine.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
The extracted context around Memantine shows recurring relationship patterns in the source. For example, Memantine → Abixa, Adaxor, Admed, Akatinol, Alceba, Alios, Almenta, Alois, Alzant, Alzer, Alzia, Alzinex, Alzixa, Alzmenda, Alzmex, As, August, Axura, Biomentin, Carrier Another extracted example is Memantine → Alzheimer's, Axura, By, CNS, Company, Eli Lilly, Germany, However, It, Merz, NMDA, Parkinson's, Prior, The. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
disease receptor nmda treatment affinity effects alzheimer's drug amantadine however receptors parkinson's antagonist use used may include review ic50 nm
TTTA extracted 218 structured relationships around Memantine. Examples in this analysis include Memantine → 3D model (JSmol) → Interactive image and Memantine → 3D model (JSmol) → as HCl: Interactive image. The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Memantine | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Memantine | 3D model (JSmol) | as HCl: Interactive image | 1.00 | infobox |
| Memantine | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Memantine | ATC code | N06DX01 (WHO) | 1.00 | infobox |
| Memantine | Bioavailability | 100% | 1.00 | infobox |
| Memantine | CAS Number | 19982-08-2 Y | 1.00 | infobox |
| Memantine | CAS Number | as HCl: 41100-52-1 | 1.00 | infobox |
| Memantine | ChEBI | CHEBI:64312 | 1.00 | infobox |
| Memantine | ChEBI | as HCl: CHEBI:64323 | 1.00 | infobox |
| Memantine | ChEMBL | ChEMBL807 Y | 1.00 | infobox |
| Memantine | ChEMBL | as HCl: ChEMBL1699 | 1.00 | infobox |
| Memantine | ChemSpider | 3914 Y | 1.00 | infobox |
| Memantine | ChemSpider | as HCl: 157849 | 1.00 | infobox |
| Memantine | CompTox Dashboard (EPA) | DTXSID5045174 | 1.00 | infobox |
| Memantine | Drug class | NMDA receptor antagonist | 1.00 | infobox |
| Memantine | DrugBank | DB01043 Y | 1.00 | infobox |
| Memantine | DrugBank | as HCl: DBSALT000456 | 1.00 | infobox |
| Memantine | ECHA InfoCard | 100.217.937 | 1.00 | infobox |
| Memantine | Elimination half-life | 60–80 hours | 1.00 | infobox |
| Memantine | Excretion | Urine (57–82% unchanged) | 1.00 | infobox |
| Memantine | Formula | C12H21N | 1.00 | infobox |
| Memantine | IUPHAR/BPS | 4253 | 1.00 | infobox |
| Memantine | KEGG | D08174 Y | 1.00 | infobox |
| Memantine | KEGG | as HCl: D04905 | 1.00 | infobox |
| Memantine | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Memantine | Legal status | BR: Class C1 (Other controlled substances) | 1.00 | infobox |
| Memantine | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Memantine | Legal status | US: ℞-only | 1.00 | infobox |
| Memantine | Legal status | EU: Rx-only | 1.00 | infobox |
| Memantine | License data | US DailyMed: Memantine | 1.00 | infobox |
The concept neighborhoods around Memantine bring nearby vocabulary together. In this analysis, examples include Treatment, Receptor and Disease. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Memantine, one of the stronger structural bridges in this analysis connects Memantine with Overview. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Memantine to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as History, Community, Culture & Applications, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Memantine · EN edition · Analysis: TopicsToTalkAbout